OrbiMed Raises $3 Billion for Global Life Sciences
The investment firm has secured significant new capital to back biopharma and medtech startups across Asia, the U.S., and Europe.
Updated on Oct. 15, 2026 in Biotech
Live Poll
Do you trust that large-scale venture capital investments in international biotech lead to better patient outcomes?
OrbiMed has raised $3 billion across its latest investment vehicles to fund global healthcare growth. This includes over $1 billion for its newest Asia-focused fund, OrbiMed Asia Partners VI.
Why it matters
The influx of capital aims to capitalize on rapid advancements in AI and new therapeutic modalities. Furthermore, the firm views China as an increasingly critical source of drug candidates for major Western pharmaceutical companies.
OrbiMed secured over $1.9 billion for its Private Investments X fund, while the new OrbiMed Asia Partners VI fund exceeded $1 billion. This follows previous Asia fund raises of $751 million and $800 million.
The players
OrbiMed
A global investment firm that manages billions of dollars in capital dedicated exclusively to the healthcare and life sciences sectors.
Forte Biosciences
A biopharmaceutical company that focuses on developing treatments for dermatological and autoimmune conditions.
Crinetics Pharmaceuticals
A clinical-stage company focused on discovering and developing therapeutics for endocrine diseases and rare endocrine-related tumors.
The details
The firm plans to deploy this capital to build and scale companies across the biopharma, medtech, and technology-enabled healthcare sectors. These investments are intended to support biotech innovation in the United States, Europe, and Asia.
Timeline
October 15, 2026: OrbiMed officially unveiled its latest private and Asian investment funds.
July 2026: Forte Biosciences and Crinetics Pharmaceuticals accepted buyout offers.
2021: OrbiMed previously raised $1.5 billion for a private investment fund.
The Tech Race
The firm is doubling down on cross-border pharmaceutical development to stay ahead in the global biotech arms race. This strategy directly leverages the trend of China serving as a vital source of drug candidates for Western pharmaceutical companies.
Investors and industry followers should monitor how this capital accelerates the transition of experimental drugs from research labs to clinical trials. Increased funding levels often signal a faster pace of development for the next generation of medical treatments.
The takeaway
The sustained capital pouring into biotech indicates strong long-term confidence in pharmaceutical R&D despite broader market fluctuations. Readers interested in the sector should watch for how these funds influence the acquisition activity seen recently with firms like Forte and Crinetics.
Further reading
For more on the current investment landscape in medical innovation, visit our Biotech section.
Live Poll
Do you trust that large-scale venture capital investments in international biotech lead to better patient outcomes?
